- Scopus BioPharma Inc SCPS has launched Duet Therapeutics that integrates the management and clinical development of the immunotherapy assets of Scopus and Olimmune.
- Related Content: Scopus BioPharma Adds Oligonucleotide Cancer Therapeutics With Olimmune Acquisition.
- The Duet Platform is comprised of three technologies, including RNA silencing (DUET-01), Antisense (DUET-02), and Protein degradation (DUET-03).
- DUET-01 is in Phase 1 clinical trial, as a monotherapy, for B-cell non-Hodgkin lymphoma.
- In 2022, Duet is targeting to file two INDs for DUET-02 in two separate indications: genitourinary and head & neck cancers.
- Duet is also evaluating combination therapies with checkpoint inhibitors.
- Price Action: SCPS stock is up 30.50% at $6.54 during the market session on the last check Thursday, before the trading was halted.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareMoversTrading IdeasGeneralBriefsPhase 1 Trialwhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
